Fake cancer drug India case reveals counterfeit Keytruda being sold to patients, raising serious safety and regulation concerns.
NEW DELHI: Fake cancer drug India case is raising alarm after a major investigation uncovered counterfeit versions of a life-saving treatment being sold to patients.
The drug in question is Keytruda, a widely used cancer therapy that can cost over ₹1.5 lakh per dose. According to the probe, fake versions were passed off as genuine using real batch numbers and even reused vials, making them extremely difficult to detect.
What makes the fake cancer drug India case especially concerning is how it allegedly involved a network of pharmacists and intermediaries. This wasn’t a one-off incident, but a coordinated effort to exploit a high-demand, high-cost treatment.
In several reported cases, patients undergoing critical care may have received these counterfeit drugs, putting their health at serious risk. For families already dealing with cancer, the possibility of ineffective or unsafe medication adds another layer of fear.
The investigation also highlights deeper issues. Gaps in regulation, weak oversight and the complexity of drug supply chains are all being questioned. Experts say this case exposes vulnerabilities that could affect other high-value medicines as well.
The fake cancer drug India case is now prompting urgent calls for tighter controls, better tracking systems and stricter enforcement across the healthcare sector.
At its core, this is about trust. When patients seek treatment, they expect it to be safe and real. Incidents like this shake that trust, and fixing it will take more than just action, it will require systemic change.
